Cargando…
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Survivin is an anti-apoptotic protein that is highly expressed in many cancers, including malignant gliomas. Preclinical studies established that the conjugated survivin peptide mimic SurVaxM (SVN53-67/M57-KLH) could stimulate an anti-tumor immune response against murine glioma in vivo, as well as h...
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5069322/ https://www.ncbi.nlm.nih.gov/pubmed/27576783 http://dx.doi.org/10.1007/s00262-016-1890-x |